A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: May 31, 2011
Last updated: February 10, 2012
Last verified: February 2012
Study to assess effect of Fluticasone Propionate on acute lung inflammation following inhaled lipopolysaccharide (LPS) challenge. Study will be conducted in healthy volunteers. Assessment of inflammation will be via sputum induction.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Fluticasone Propionate
Drug: Placebo for Fluticasone Propionate
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: A Randomized, Double-Blind (3rd Party Open), Placebo-Controlled, 2-Way Crossover Study To Determine The Effects Of A Single Inhaled Dose Of 500 MCG Fluticasone Propionate On Induced Sputum Neutrophils Following Inhaled Lipopolysaccharide (LPS) Challenge In Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Sputum Neutrophil (%) [ Time Frame: 6 hours post LPS challenge ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Sputum Inflammatory cytokines (IL-6, MCP-1 and MIP1beta) [ Time Frame: 6 hours post LPS challenge ] [ Designated as safety issue: No ]
  • Blood Inflammatory Cytokines (IL-6, MCP-1, fibrinogen, CC16, CRP and MIP1beta) [ Time Frame: 1, 4 and 6 hours post LPS challenge ] [ Designated as safety issue: No ]
  • Sputum cells (macrophages and total cell count) [ Time Frame: 6 hours post LPS challenge ] [ Designated as safety issue: No ]

Enrollment: 17
Study Start Date: July 2011
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Fluticasone Propionate
Dry powder for inhalation, Single Dose, 500mcg
Placebo Comparator: Arm 2 Drug: Placebo for Fluticasone Propionate
Dry powder for inhalation, Single Dose, placebo

Detailed Description:
Methodology Validation

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers
  • Normoresponsive airways - histamine PC20>16mg/mL
  • Able to complete sputum induction successfully

Exclusion Criteria:

  • Non (or ex) smokers
  • No LPS challenge in previous 4 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01364519

United Kingdom
Pfizer Investigational Site
Manchester, Greater Manchester, United Kingdom, M23 9QZ
Pfizer Investigational Site
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01364519     History of Changes
Other Study ID Numbers: A9011082 
Study First Received: May 31, 2011
Last Updated: February 10, 2012
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Pfizer:

Additional relevant MeSH terms:
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Lung Diseases
Lung Diseases, Obstructive
Pathologic Processes
Respiratory Tract Diseases
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Dermatologic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 04, 2016